Investigational extended-release topical formulation decreases eczema severity

More adults with moderate to severe atopic dermatitis receiving an investigational extended-release topical formulation vs. a vehicle treatment lowered their eczema severity by 50% in 4 weeks, according to interim phase 2 trial results.The formulation, GX-03 (Turn Therapeutics), “provide[s] sustained localized exposure to polyhexanide at the skin surface,” according to the company